CBD Oil For Dystonia Abstracts from the International Congress of Parkinson’s and Movement Disorders. A real-life study of Medical Cannabis effect on adults with dystonia S. Anis, A. The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients A clinical trial is planned to study the effects of cannabis on dystonia and spasticity in children with neurological
CBD Oil For Dystonia
Abstracts from the International Congress of Parkinson’s and Movement Disorders.
A real-life study of Medical Cannabis effect on adults with dystonia
S. Anis, A. Faust-Socher, D. Sverdlov, N. Hezi, N. Giladi, T. Gurevich (Tel Aviv, Israel)
Objective: To assess the effect of Medical Cannabis (MC) on patients with dystonia.
Background: MC has been suggested to treat involuntary contractions of muscles in patients with dystonia and alleviate related pain, in a few case reports and case series. The suggested mechanism is activation of cannabinoid receptors in the basal ganglia, enhancing the release of γ-aminobutyric acid (GABA). MC is approved by the Israeli Ministry of Health (MOH) since 2013 for symptomatic treatment in patients with movement disorders accompanied by pain.
Method: Patients with dystonia of all types (primary and secondary, focal, segmental, generalized) with an MOH approved MC license were interviewed via phone regarding treatment efficacy and side effect profile from chronic MC consumption. Global efficacy was rated on a Likert scale of 1-5.
Results: Twelve patients with dystonia (6 females, mean age 54.6) were interviewed for this study. Three patients suffered from focal dystonia, seven patients from generalized dystonia and two patients from hemi-dystonia. The etiology of the dystonia was known in 5 patients (DYT1, DYT6 and three patients with Parkinson’s disease). Duration of MC use (years) was 2.80±0.79, average dose of MC (grams/month) was 34.29±5.68, %THC 11.63±2.12, %CBD 9.44±1.47, mode of administration: cigarettes/vapor (42%), oil (42%), both (16%), frequency of use 4.73±1.54 (per day), number of puffs/drops for each use 6.60±1.88. The total global impression efficacy score for dystonia was 3.16 out of a total 5 possible points. Efficacy for pain was 3.67 out of 5. Nine out of twelve patients reported improvement in sleep. Most common side effects were dry mouth (75%) and fatigue (50%). Five patients (42%) suffered from psychiatric side effects: three suffered from anxiety (one with hallucinations) while two suffered from mood worsening (one with suicidal thinking) soon after treatment initiation. Side effects resolved in 4 patients after treatment modification and only one patient had to stop treatment. One patient stopped treatment due to inefficacy.
Conclusion: MC seems to mitigate dystonic muscle activity and related pain. Psychiatric side effects of MC treatment have to be monitored especially following treatment initiation. Larger cohort should be further investigated to determine MC efficacy, mechanism of action, optimal doses and the best THC/CBD ratio for the treatment of dystonia.
The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients
A clinical trial is planned to study the effects of cannabis on dystonia and spasticity in children with neurological diseases. The clinical trial will include 40 children divided into two groups: children with spasticity and dystonia due to cerebral palsy, and children with spasticity and dystonia due to genetic neurodegenerative diseases. Each group will be randomly divided into two arms and will receive Avidekel cannabis oil 6-to-1 ratio of CBD to THC or enriched Avidekel cannabis oil 20-to-1 ratio of CBD to THC. During the study, various variables will be collected including: medication intake, spasticity, dystonia score, pain scale, restlessness scale, quality of life measures, safety tests, side effects, and an addiction test. The investigators hypothesize that cannabis consumption will reduce dystonia and spasticity in children with motor disability related to genetic neurodegenerative diseases and cerebral palsy and as a result improve motor function, non-motor functions and quality of life.
|Condition or disease||Intervention/treatment||Phase|
|Spasticity Dystonia||Drug: Avidekel oil Drug: Enriched Avidekel oil||Phase 2|
The purpose of this study is to examine the effect of two cannabis oils containing the main cannabinoid Δ9 -THC and CBD ratio of 1 to 6 and 1 to 20 (respectively), on spastic movement disorder and dystonia.
40 children will be enrolled in this study and will be divided into 2 groups:
- Children with spasticity and dystonia due to cerebral palsy
- Children with spasticity and dystonia due to genetic neurodegenerative diseases
Each group will be randomly divided into two groups:
I. Active comparator: 6-to-1 ratio of CBD to THC oil II. Active comparator: 20-to-1 ratio of CBD to THC oil
During the study the following variables will be collected:
- Consumption of drugs medication intake
- Spasticity grade measured using the Modified Ashworth Scale
- Dystonia grade measured using the Barry Albright Dystonia Scale
- Patient’s subjective report about the severity of his/her spasticity and/or dystonia
- Pain scale
- Restlessness scale
- Quality of life measures: function, sleep, mood , appetite , weight
- Safety tests: liver function, renal function, blood tests (complete blood chemistry), blood pressure, pulse, ECG
- Side effects
- Addiction test
The purposes of the study:
- Efficiency – examining the effect of cannabis on dystonia and spasticity.
- Examining the most effective cannabinoid ratio for the relief of dystonia and spasticity. (Δ9 -THC and CBD ratio of 1 to 6 or 1 to 20, respectively).
- Examining the effect of cannabis on quality of life measures (such as medication intake, mood, appetite, sleep).
- Safety: examination of side effects and unwanted effects of cannabis and its limitations.
Research Hypothesis: The investigators hypothesize that cannabis consumption will reduce dystonia and spasticity symptoms in children with motor disability related to genetic neurodegenerative diseases and cerebral palsy and as a result improves motor function, non-motor function and quality of life.